Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wet chemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Wet chemistry. Displaying page 1 of 1.
    EudraCT Number: 2017-002487-41 Sponsor Protocol Number: GLY-321-2017 Start Date*: 2018-01-31
    Sponsor Name:GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG)
    Full Title: A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome
    Medical condition: Short bowel syndrome (SBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000590-93 Sponsor Protocol Number: CR213-20 Start Date*: 2023-06-09
    Sponsor Name:CuraTeQ Biologics Private Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (N...
    Medical condition: Wet (Neovascular) Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001244-26 Sponsor Protocol Number: COV-2-SOLNATIDE-20 Start Date*: 2020-04-11
    Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria
    Full Title: COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.
    Medical condition: Pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037423 Pulmonary oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022121-15 Sponsor Protocol Number: 4618-008 Start Date*: 2011-04-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 52-week Extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) DK (Completed) AT (Completed) NO (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003855-47 Sponsor Protocol Number: AP301-II-002 Start Date*: 2018-02-27
    Sponsor Name:Apeptico Forschung und Entwicklung GmbH
    Full Title: Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability oedema in patients with moderate-to-severe ARDS - a randomised, placebo-controlle...
    Medical condition: pulmonary permeability oedema in patients with moderate-to-severe ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037423 Pulmonary oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002930-19 Sponsor Protocol Number: XBR1001 Start Date*: 2019-02-25
    Sponsor Name:Xbrane Biopharma
    Full Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Wet Age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) HU (Completed) SK (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-005129-99 Sponsor Protocol Number: TA799-013 Start Date*: 2021-02-10
    Sponsor Name:VectivBio AG
    Full Title: A multicenter, open-label, metabolic balance study to evaluate the effects of apraglutide on intestinal absorption in adult subjects with short bowel syndrome, intestinal failure (SBS-IF), and colo...
    Medical condition: short bowel syndrome, intestinal failure (SBS-IF), colon-in-continuity (CIC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002486-21 Sponsor Protocol Number: GLY-311-2017 Start Date*: 2018-01-18
    Sponsor Name:GLyPharma Therapeutic, Inc. (a wholly owned subsidiary of VectivBio Holding AG)
    Full Title: A once weekly, repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and pharmacodynamics of FE 203799 in patients with short bowel syndrome wi...
    Medical condition: Short Bowel Syndrome (SBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001201-75 Sponsor Protocol Number: FHP-2021-2-26 Start Date*: 2021-09-13
    Sponsor Name:Female Healthcare Purna
    Full Title: A Phase 2, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Miconazole Nitrate 2% + Domiphen Bromide Vaginal cream in the Treatment of Subjects with Acute Vu...
    Medical condition: acute vulvovaginal candidiasis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000243-24 Sponsor Protocol Number: MD7114987 Start Date*: 2011-06-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: An open-label, phase 2a study to evaluate pazopanib eye drops administered for 12 weeks to patients with neovascular agerelated macular degeneration
    Medical condition: Age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004917-26 Sponsor Protocol Number: PS-G202 Start Date*: 2016-11-08
    Sponsor Name:Parion Sciences, Incorporated
    Full Title: A Phase 2a, Two-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivac...
    Medical condition: Primary Ciliary Dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10069713 Primary ciliary dyskinesia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 17:43:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA